Renal calcium handling after rapamycin conversion in chronic allograft dysfunction

Mai Szu Wu, Cheng Chieh Hung, Chiz Tzung Chang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To study the effect of rapamycin on calcium balance, we conducted a prospective study on transplant recipients. The patients were converted to rapamycin and observed for 6 months (C). Urinary Ca and P, ALK-p, Ca, P, and intact parathyroid hormone (iPTH) were examined before and 6 months after conversion. A nonconversion group (N) was found for comparison. Sixteen patients entered the study. There were increases of ALK-p (C: 67.4 ± 32.9 to 79.6 ± 37.0*; N: 67.3 ± 25.1 to 67.8 ± 14.7 IU) (*P <0.05), Ca 2+ (C: 8.7 ± 0.3 to 9.5 ± 0.2*; N: 8.8 ± 0.4 to 8.7 ± 0.5 mg/dl), urinary P excretion (C: 287.6 ± 257.1 to 439.4 ± 260.9*; N: 233.9 ± 117.2 to 264.8 ± 143.4 mg/day) and iPTH (C: 133.7 ± 149.6 to 200.6 ± 171.5*; N: 128.4 ± 57.1 to 136.3 ± 40.4 pg/ml). Serum P (C: 5.3 ± 1.4 to 3.6 ± 0.6*; N: 5.2 ± 0.8 to 5.1 ± 0.9 mg/dl) and urinary Ca 2+ (C: 93.9 ± 52.6 to 31.8 ± 45.1*; N: 84.6 ± 38.3 to 75.9 ± 38.4 mg/day) were decrease. Rapamycin was associated with decreased urinary Ca 2+ and increased P excretion. The alteration might come from the increased parathyroid hormone.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalTransplant International
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 2006
Externally publishedYes

Fingerprint

Sirolimus
Parathyroid Hormone
Allografts
Calcium
Kidney
Prospective Studies
Serum

Keywords

  • Calcium
  • Parathyroid hormone
  • Phosphate
  • Rapamycin

ASJC Scopus subject areas

  • Transplantation

Cite this

Renal calcium handling after rapamycin conversion in chronic allograft dysfunction. / Wu, Mai Szu; Hung, Cheng Chieh; Chang, Chiz Tzung.

In: Transplant International, Vol. 19, No. 2, 02.2006, p. 140-145.

Research output: Contribution to journalArticle

Wu, Mai Szu ; Hung, Cheng Chieh ; Chang, Chiz Tzung. / Renal calcium handling after rapamycin conversion in chronic allograft dysfunction. In: Transplant International. 2006 ; Vol. 19, No. 2. pp. 140-145.
@article{e35549c7724e40aa813f0619b3cf1439,
title = "Renal calcium handling after rapamycin conversion in chronic allograft dysfunction",
abstract = "To study the effect of rapamycin on calcium balance, we conducted a prospective study on transplant recipients. The patients were converted to rapamycin and observed for 6 months (C). Urinary Ca and P, ALK-p, Ca, P, and intact parathyroid hormone (iPTH) were examined before and 6 months after conversion. A nonconversion group (N) was found for comparison. Sixteen patients entered the study. There were increases of ALK-p (C: 67.4 ± 32.9 to 79.6 ± 37.0*; N: 67.3 ± 25.1 to 67.8 ± 14.7 IU) (*P <0.05), Ca 2+ (C: 8.7 ± 0.3 to 9.5 ± 0.2*; N: 8.8 ± 0.4 to 8.7 ± 0.5 mg/dl), urinary P excretion (C: 287.6 ± 257.1 to 439.4 ± 260.9*; N: 233.9 ± 117.2 to 264.8 ± 143.4 mg/day) and iPTH (C: 133.7 ± 149.6 to 200.6 ± 171.5*; N: 128.4 ± 57.1 to 136.3 ± 40.4 pg/ml). Serum P (C: 5.3 ± 1.4 to 3.6 ± 0.6*; N: 5.2 ± 0.8 to 5.1 ± 0.9 mg/dl) and urinary Ca 2+ (C: 93.9 ± 52.6 to 31.8 ± 45.1*; N: 84.6 ± 38.3 to 75.9 ± 38.4 mg/day) were decrease. Rapamycin was associated with decreased urinary Ca 2+ and increased P excretion. The alteration might come from the increased parathyroid hormone.",
keywords = "Calcium, Parathyroid hormone, Phosphate, Rapamycin",
author = "Wu, {Mai Szu} and Hung, {Cheng Chieh} and Chang, {Chiz Tzung}",
year = "2006",
month = "2",
doi = "10.1111/j.1432-2277.2005.00251.x",
language = "English",
volume = "19",
pages = "140--145",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Renal calcium handling after rapamycin conversion in chronic allograft dysfunction

AU - Wu, Mai Szu

AU - Hung, Cheng Chieh

AU - Chang, Chiz Tzung

PY - 2006/2

Y1 - 2006/2

N2 - To study the effect of rapamycin on calcium balance, we conducted a prospective study on transplant recipients. The patients were converted to rapamycin and observed for 6 months (C). Urinary Ca and P, ALK-p, Ca, P, and intact parathyroid hormone (iPTH) were examined before and 6 months after conversion. A nonconversion group (N) was found for comparison. Sixteen patients entered the study. There were increases of ALK-p (C: 67.4 ± 32.9 to 79.6 ± 37.0*; N: 67.3 ± 25.1 to 67.8 ± 14.7 IU) (*P <0.05), Ca 2+ (C: 8.7 ± 0.3 to 9.5 ± 0.2*; N: 8.8 ± 0.4 to 8.7 ± 0.5 mg/dl), urinary P excretion (C: 287.6 ± 257.1 to 439.4 ± 260.9*; N: 233.9 ± 117.2 to 264.8 ± 143.4 mg/day) and iPTH (C: 133.7 ± 149.6 to 200.6 ± 171.5*; N: 128.4 ± 57.1 to 136.3 ± 40.4 pg/ml). Serum P (C: 5.3 ± 1.4 to 3.6 ± 0.6*; N: 5.2 ± 0.8 to 5.1 ± 0.9 mg/dl) and urinary Ca 2+ (C: 93.9 ± 52.6 to 31.8 ± 45.1*; N: 84.6 ± 38.3 to 75.9 ± 38.4 mg/day) were decrease. Rapamycin was associated with decreased urinary Ca 2+ and increased P excretion. The alteration might come from the increased parathyroid hormone.

AB - To study the effect of rapamycin on calcium balance, we conducted a prospective study on transplant recipients. The patients were converted to rapamycin and observed for 6 months (C). Urinary Ca and P, ALK-p, Ca, P, and intact parathyroid hormone (iPTH) were examined before and 6 months after conversion. A nonconversion group (N) was found for comparison. Sixteen patients entered the study. There were increases of ALK-p (C: 67.4 ± 32.9 to 79.6 ± 37.0*; N: 67.3 ± 25.1 to 67.8 ± 14.7 IU) (*P <0.05), Ca 2+ (C: 8.7 ± 0.3 to 9.5 ± 0.2*; N: 8.8 ± 0.4 to 8.7 ± 0.5 mg/dl), urinary P excretion (C: 287.6 ± 257.1 to 439.4 ± 260.9*; N: 233.9 ± 117.2 to 264.8 ± 143.4 mg/day) and iPTH (C: 133.7 ± 149.6 to 200.6 ± 171.5*; N: 128.4 ± 57.1 to 136.3 ± 40.4 pg/ml). Serum P (C: 5.3 ± 1.4 to 3.6 ± 0.6*; N: 5.2 ± 0.8 to 5.1 ± 0.9 mg/dl) and urinary Ca 2+ (C: 93.9 ± 52.6 to 31.8 ± 45.1*; N: 84.6 ± 38.3 to 75.9 ± 38.4 mg/day) were decrease. Rapamycin was associated with decreased urinary Ca 2+ and increased P excretion. The alteration might come from the increased parathyroid hormone.

KW - Calcium

KW - Parathyroid hormone

KW - Phosphate

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=33645371521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645371521&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2005.00251.x

DO - 10.1111/j.1432-2277.2005.00251.x

M3 - Article

VL - 19

SP - 140

EP - 145

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 2

ER -